In this week’s issue:
- The Faculty of Medicine internal deadline for CIHR Fellowship Awards is Thursday, November 6th, 2014. Please visit our website for complete procedures and timelines (final reminder).
- US Department of Defense – Orthotics and Prosthetics Outcomes Research Award
- Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials
- WorksafeBC – Innovation at Work
- California Table Grape Commission – 2015-16 Health Research Grant Program
- CIHR – SPOR Networks in Chronic Diseases
- Prostate Cancer Canada – Targeted RFA in Survivorship Research
- Bill & Melinda Gates Foundation – Grand Challenges (reminder)
- American Pain Society – 2015 Rita Allen Award in Pain
- American Roentgen Ray Society – Neuroradiology Scholarship
Awards and Honours:
- Canadian Cancer Society – Awards for Excellence in Cancer Research
- First International Conference on Weaver Syndrome (final reminder)
- UBC Neglected Global Diseases Initiative – Ebola Symposium for Treatment and Action
- Centre for Blood Research – The Earl W. Davie Symposium (final reminder)
- German Academic Exchange Association (DAAD) – RISE Worldwide 2015
Pre-application Deadline: November 12, 2014; 2pm PST
The Orthotics and Prosthetics Outcomes Research Award (OPORA) is being offered for the first time in FY14. It is intended to support research that evaluates the comparative effectiveness of and functional outcomes associated with prosthetic and orthotic clinical interventions and/or other rehabilitation interventions for Service Members and Veterans who have undergone limb salvage or limb amputation. The goal is to improve our understanding and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers. Proposed projects should be designed to provide outcomes data regarding orthotic and prosthetic devices, and/or related clinical interventions and must include the anticipated effect on patient care metrics. Collaboration with military researchers and clinicians is encouraged, as are joint Department of Defense (DoD)-VA studies, including longitudinal outcome studies.
The FY14 OPORA offers two funding levels:
- Funding Level 1:
The maximum period of performance is 2 years.
The maximum allowable total (direct and indirect) costs for the entire period of performance are $500,000.
- Funding Level 2:
The maximum period of performance is 3 years.
The allowable range of total (direct and indirect) costs for the entire period of performance is between $500,000 and $3.5 million (M), depending on the individual research project.
The requested budget level should be appropriate for the scope of research proposed.
For further information, please visit the OPORA website.
LOI Deadline: November 21, 2014
Many treatments for Alzheimer’s disease have been shown to be safe and to have some positive effect in animal models. However, many of these potentially successful drugs have not been brought to human trial because of the increased cost and risk at that stage of research.
The Alzheimer’s Drug Discovery Foundation is responding to this problem with the Alzheimer’s Program to Accelerate Clinical Trials (PACT). The goal of the program is to increase the number of innovative drugs for Alzheimer’s disease tested in humans. To that end, grants of up to $1.5 million will be awarded for biomarker-based pilot clinical trials.
Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies — both public and private — anywhere in the world.
Letters of Intent must be received no later than November 21, 2014. Upon review, selected applicants will be invited to submit full applications, which will be due December 5, 2014.
Please review the application details within the PACT Request for Proposals.
Notice of Intent Deadline: November 24, 2014
Innovation at Work is intended to provide funding for small-scale projects that promote increased interaction between workplace parties, organizations, and/or researchers. Using the collective resources of those who are most affected by its policies and programs helps WorkSafeBC and employers to ensure that critical areas of need are addressed and practical solutions are found and implemented. The maximum grant for these projects is normally $50,000, for a maximum duration of one year. Anyone is eligible to apply — the experience and capability of the project team will be a primary consideration.
For further information, please visit the WorksafeBC website.
LOI Deadline: November 25, 2014; 5pm
Over 14 years ago, California’s fresh grape growers established a health research grant program to help discover how and why grapes are beneficial to health.
Each fall, Letters of Intent are solicited from the research community. These are reviewed and finalists are invited to submit full proposals. The commission’s scientific advisory panel of distinguished researchers conducts the rigorous grant review and selection.
The grape research has covered a wide range of health topics including heart, joint, brain, and eye health, as well as certain cancers. To view the list of supported research to date click here.
Grape research is conducted using a freeze-dried whole grape powder, designed to facilitate reproducible data and to provide researchers with a grape sample that is available year round. For human studies, a grape powder placebo is made available.
Please visit the California Table Grape Commission website for further details.
Registration Deadline: December 2, 2014
Application Deadline: January 13, 2015
Patient-oriented research, a cornerstone of evidence-informed health care, refers to a continuum of research, from initial studies in humans to comparative effectiveness and outcomes research, and the integration of this research into the health care system and clinical practice.
Canada’s Strategy for Patient-Oriented Research (SPOR) is a strategy that puts patients first. It was officially launched in August 2011 after extensive consultation with national and international partners. The strategy is led by a National Steering Committee: a coalition of federal, provincial and territorial partners with broad representation of patients, policy makers, researchers and clinicians.
The investment in and implementation of SPOR reflects a commitment by the federal, provincial and territorial governments and partners to deliver high quality care in Canada by providing patients, health professionals and policy makers with the best available information to make decisions about health care. It aims to strengthen support for clinical trials and intervention studies as well as research that compares the effectiveness, benefits and harms of existing treatment options. The strategy also endeavours to improve the translation of innovative preventative, diagnostic and therapeutic approaches into the health care setting by expanding research in implementation science and incorporating these methods into day to day practice.
The vision of the strategy is that Canada will demonstrably improve health outcomes and enhance the health care experience for patients through the integration of evidence at all levels of the health care system.
Research and knowledge translation networks are one of the five core elements designed to realize the vision of SPOR. SPOR Networks are national, multi-institutional, multi-disciplinary and collaborative and are comprised of collaborations of patients, health professionals, decision makers, health researchers and other stakeholders. These networks are expected to develop important and effective relationships with the other core elements of SPOR and where appropriate, with other SPOR Networks.
This funding opportunity will provide support for the development and implementation of SPOR Networks in non-communicable Chronic Diseases. For the purpose of this opportunity, non-communicable chronic disease is defined as a long-term disease that is not passed from one person to another; it evolves over time, often progressing in severity. Although a non-communicable chronic disease may be prevented and can often be controlled, it is rarely cured.
Total funding available from CIHR for this initiative is $50.8M:
- $1.0M will be available to fund up to 20 Development Grants through the Letter of Intent stage of this opportunity. Each Development Grant will have a maximum value of $50,000. Partner funds are NOT required at this stage.
- $49.8M will be available to fund up to four distinct networks. Each successful network will receive up to $12,450,000 over five years from CIHR and must be matched at a minimum of 1:1 with funding from non-federal sources. Partner funds ARE required at the full application stage.
Please visit the CIHR website for full details.
Registration Deadline: December 5, 2014
Full Application Deadline: January 15, 2015
Prostate Cancer Canada (PCC) invites applications for investigator-initiated grants in survivorship research. This request for applications (RFA) solicits research proposals from groups taking novel approaches to studies focusing on the behavioural, physical, psychosocial, social/family, mental, functional, spiritual, emotional and practical concerns of daily living. Projects should aim to inform the development and delivery of interventions and best practices in follow-up care for cancer patients, survivors and their families and caregivers
Award amount: up to $1.5M over 5 years
Please visit the PCC website for further details.
Deadline: January 13, 2015
The Bill & Melinda Gates Foundation is now inviting applications for three new Grand Challenges:
- Putting Women and Girls at the Center of Development
- Creating and Measuring Integrated Solutions for Healthy Birth, Growth, and Development (part of the All Children Thriving platform)
- New Interventions for Global Health
Applications for these new challenges will be accepted beginning on November 4, 2014. Please also note that we are still accepting applications for six Grand Challenges Explorations topics.
For links to more information on these challenges, please visit the grant opportunity page at www.grandchallenges.org, which features a new homepage to support the next phase of Grand Challenges launched today with international partners at the 10th annual Grand Challenges meeting.
Deadline: January 16, 2015
The Rita Allen Foundation and the American Pain Society are accepting applications for the 2015 Rita Allen Award in Pain.
Proposed research projects should be directed toward the molecular biology of pain and/or basic science topics related to the development of new analgesics for the management of pain due to terminal illness.
Eligible candidates must have completed their training and be able to provide persuasive evidence of distinguished achievement or extraordinary promise in basic science research in pain. In addition, candidates must be in the early stages of their career with an appointment at the faculty level.
To be eligible, applicants must demonstrate the strong support of the appropriate administrators and department chair or institute head; have been on a tenure track for no more than three years (support will be reconsidered if a Rita Allen Foundation Scholar is awarded tenure); and conduct his or her research at an institution in the United States or Canada.
The program will award two grants in the amount of $50,000 a year, for a period of up to three years. The entire award must be allocated to projects specifically chosen by the recipient. Institutional overhead is not supported, but eligible grant expenses may include the principal investigator’s salary.
Complete program guidelines and application instructions are available at the American Pain Society website.
Application Deadline: January 11, 2016
The American Roentgen Ray Society, in partnership with the American Society of Neuroradiology, is accepting applications for its 2015 ARRS/ASNR Scholarship program.
This scholarship is awarded every other year and will next be awarded in Spring 2016.
The purpose of the ARRS/ASNR Scholarship is to establish the recipient as an independent investigator in the field of neuroradiology and to collect preliminary data that could lead to further funding through established mechanisms such as the NIH. The scholarship program is open to junior full time faculty members (below the associate professor level) specializing in neuroradiology. Applications will be accepted in any area of research related to brain, spine and head and neck imaging. Applications should describe the unique nature of the research effort independent of existing research efforts, and should have well-defined goals for the funding period of the grant. Greater emphasis on the independent nature of the research will be stressed compared to resident/fellowship efforts.
The program is open to junior full-time faculty members (below the associate professor level) specializing in neuroradiology. Applications will be accepted in any area of research related to brain, spine, and head and neck imaging. In addition, applicants must be a member of both ARRS and ASNR at the time of application and for the duration of the award.
Visit the ARRS website for complete program guidelines and application instructions.
AWARDS AND HONOURS:
Nomination Deadline: November 28, 2014
The Canadian Cancer Society is pleased to invite you to submit nominations for each of the Society’s four prestigious Awards for Excellence in Cancer Research for 2014. I encourage you to nominate deserving individuals who have made, and are making, valuable contributions to cancer research and cancer control in Canada. The awards include the Canadian Cancer Society Robert L. Noble Prize, Canadian Cancer Society O. Harold Warwick Prize, Canadian Cancer Society William E. Rawls Prize and the Canadian Cancer Society Bernard and Francine Dorval Prize. Descriptions of the award categories and detailed nomination criteria are attached. In addition to nominating worthy candidates, individuals can nominate themselves.
Each Award comes with a $20,000 contribution to the recipient’s research program. More than that, the awards are an opportunity to keep the public informed of the successes in Canadian research by highlighting the progress achieved by the cancer research community and attracting more young people to pursue a career in this field.
For more information about the 2014 Canadian Cancer Society Awards for Excellence, please visit the CCS website.
Date & Time: November 9, 2014, 9am-6pm
Location: Hyatt Regency Vancouver, 655 Burrard St, Vancouver
It is with great pleasure that we announce the First International Conference on Weaver Syndrome, to take place Sunday, November 9th, 2014 at the Hyatt Regency Hotel, Vancouver.
The conference is intended to be of interest to families affected by Weaver syndrome and related overgrowth conditions, as well as to physicians, scientists and academic trainees with an interest in Weaver syndrome, genetic and epigenetic overgrowth syndromes, and rare disorders in general.
It will be a satellite meeting the day following the Canadian College of Medical Geneticists’
annual meeting (scheduled for November 6-8, 2014), on the same site as the CCMG meeting (i.e. at the Hyatt Regency Hotel, Vancouver).
Professor David Weaver (First to describe the syndrome that now bears his name) Topic: Historical Retrospective of the Description of Weaver syndrome and clinical overview of features
Dr. Steven JM Jones (Head of Bioinformatics, Michael Smith Genome Sciences Centre) Topic: Next-generation sequencing methods for gene discovery and diagnosis
Dr. Serena Buontempo (Stem Cell specialist from Italy) Topic: Stem Cells – Lessons from EZH2-mutant cell lines and applications for Weaver syndrome
There will also be 3-4 trainee talks for graduate students and postdoctoral fellows.
The current schedule is for 3 talks in the morning 9am-12pm, lunch break for 1 hour then talks 2pm-3pm with trainee talks 3pm-4pm and then a family event.
Tickets are free for the scientific portion of the conference. There may be a separate fee for the family social event afterwards. Registration is available here:
If you do not wish to use the Eventbrite service, please contact the organizer, Dr. William Gibson, to register.
Date & Time: November 13, 2014; 1-5:30 pm, reception following
Location: London Drugs Theatre, Pharmaceutical Sciences, 2304 Wesbrook Mall, Vancouver BC
There are presently three Canadian contributions to potential therapeutics and vaccines for the Ebola Virus Disease that are being fast-tracked through clinical trials. Two of these are TKM-Ebola and ZMapp. Our two keynote speakers will discuss the science behind these interventions. Our expert panel members will present and discuss on a wide-range of topics about Ebola: public health, methods of fast-tracking clinical trials, infection control and working in the field. More speakers may be added soon… Reserve your ticket now.
Keynote Presentations of Canada’s contributions:
Dr. Ian MacLachlan Executive Vice President and Chief Technical Officer, Tekmira Pharmaceuticals Corporation
Dr. Xiangguo Qiu Head of Serology Diagnostics Unit in Special Pathogens, National Microbiology Laboratories, Public Health Agency of Canada
Expert Panel Presentations
Jan Hajek, MD FRCPC Clinical Assistant Professor, Division Infectious Diseases, Department of Medicine, Faculty of Medicine, UBC
Bonnie Henry, MD MPH Deputy Provincial Health Officer, British Columbia Ministry of Health; Associate Professor, School of Population and Public Health, Faculty of Medicine, UBC
Titus Wong, BScPharm MD FRCPC, Medical Microbiology and Infection Control, VGH Department of Pathology and Laboratory Medicine, Faculty of Medicine, UBC
Steve Kanters, PhD(c) MSc Research Associate, Centre for Clinical Epidemiology and Evaluation; and Research Manager and Statistician, Global Evaluative Sciences
Srinivas Murthy, MD Clinical Assistant Professor, Div of Critical Care, Pediatrics, Faculty of Medicine, UBC
To reserve your seat for this free symposium http://ngdi-ubc-ebola.eventbrite.ca
For questions or more information please contact Jocelyn at email@example.com.
Date: November 13, 2014
Location: SFU Harbour Centre, 515 West Hastings St., Vancouver BC
Keynote Speakers: Philip Majerus & Denisa Wagner
Special Guest: David Gailani & Jay Degen
The goal of the Earl W. Davie Symposium is to widely communicate cutting edge advances in the broad field of hemostasis-thrombosis, as applied to medically relevant disciplines including innate immunity, infectious diseases, inflammation and cancer.
Submit abstracts for posters, and register now at www.cbr.ubc.ca.
A preliminary program is available at http://www.scribd.com/doc/238567901/Earl-W-Davie-Symposium-2014-Preliminary-Program.
Proposal Submission Deadline: November 30, 2014
RISE Worldwide is a funded opportunity to engage high-quality, international undergraduate students from Germany for an approximate 12-week research internship in the summer of 2015. Each successful RISE participant will receive a scholarship from the German Academic Exchange Association (DAAD) that includes a monthly allowance, travel support and insurance.
Please note that project proposals from eligible faculty members, researchers affiliated with UBC, Postdocs and PhD students are now being accepted by the DAAD until November 30.
All details about the program have been posted at https://faculty-staff.grad.ubc.ca/graduate-recruitment-initiative/rise-worldwide (CWL required).
UBC has participated in the RISE Worldwide program since 2009 and hosted more than 70 students for short-term research projects at UBC.